Slide 1: Q1 2026 Financial Results
Q1 2026 Financial Results As of March 31, 2026, reported on May 7, 2026 NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 1
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our g
Slide 3: Sanjiv Razdan, CEO, President and Director
Sanjiv Razdan CEO, President and Director NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 3
Slide 4: Joint 2.0
Joint 2.0 the first phase of our transformation journey is largely complete, driving renewed growth and stronger profitability ✓ Significantly strengthened management team ✓ Effectively completed refranchising initiative ✓ Continued focus on cost discipline across operations ✓ Positioning company fo
Slide 5: Q1 2026 Year-over-Year Improvements
Q1 2026 Year-over-Year Improvements + 13% +$ 2.2M +$ 1.6M +$2.3M Revenue From Adjusted EBITDA From Net Income From Free Continuing Operations Continuing Operations Continuing Operations Cash Flow Cash flow from operating activities improved by $2.2M NASDAQ: JYNT | © 2026 The Joint Corp. All Rights R
Slide 6: Refranchising Company-Owned Clinics
Refranchising Company-Owned Clinics • Signed Asset Purchase Agreement for the sale of 45 corporate- owned or managed clinics in April 2026, for $2.3M • Letter of Intent for sale of five additional corporate-owned or managed clinics in Q1 2026 • Only three company-owned clinics will remain following
Slide 7: Joint 3.0
Joint 3.0 the next phase of our journey ✓ Leveraging positive consumer trends around: • Longevity; health span; mindfulness; sleep quality; non-invasive whole-body care ✓ Prioritizing growth through new channels • Expansion into underpenetrated U.S. markets • B2B • Potential entry into first interna
Slide 8: Driving Top-Line Momentum
Driving Top-Line Momentum Messaging continues to be on chiropractic care for pain relief, and helping patients get back to what they love to do • National Marketing: began high-impact media program in November 2025 which is helping drive monthly sequential improvement in active member growth • Ongoi
Slide 9: Patient Engagement
Patient Engagement • Q1 comp sales reflect macro-economic headwinds • Expect comp sales trends will improve throughout the balance of 2026 • Four consecutive months of sequential improvement in active member count per clinic • Focused on driving stronger lead generation, better in-clinic conversion,
Slide 10: Scott Bowman, Chief Financial Officer
Scott Bowman Chief Financial Officer NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 10
Slide 11: Operating Metrics
Operating Metrics • $126.1M Q1 2026 system-wide sales1 (4.9)% vs Q1 2025 • (4.2)% Q1 2026 comp sales2 vs Q1 2025 • $3.5M Q1 2026 consolidated Adjusted EBITDA +22% vs Q1 2025 1 System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franc
Slide 12: Three Months Ended March 31, 2026
Three Months Ended March 31, 2026 3 months ended 3 months ended $ in Millions 1 Difference 03/31/26 03/31/25 Revenue $14.8 $13.1 +$1.7 Cost of revenues $2.7 $3.0 ($0.3) Selling and marketing $3.7 $3.5 +$0.2 Depreciation and amortization $0.4 $0.4 - G&A $7.1 $6.9 +$0.2 Net income / (loss) from contin
Slide 13: Clinic Portfolio
Clinic Portfolio TOTAL CLINICS OPEN at quarter-end 967 9601 935 9431 Franchised 75 75 125 Company-owned or managed 838 135 126 706 96 579 513 64 442 60 399 48 842 885 868 370 800 47 312 61 712 246 47 610 4 515 453 352 394 265 309 242 175 82 12 26 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 202
Slide 14: Strong Balance Sheet & Focused Capital Allocation
Strong Balance Sheet & Focused Capital Allocation $ in Millions 03/31/26 12/31/25 Unrestricted cash $20.7 $23.6 Restricted cash $0.7 $0.7 Availability on $20 Million JP Morgan Chase LOC $20.0 $20.0 Stock repurchase plan • Repurchased 137,000 shares for $1.1M during Q1 2026, at an average price of $8
Slide 15: Reiterating 2026 Guidance Metrics
Reiterating 2026 Guidance Metrics 2026 Guidance 2025 Low High Actual System-wide Sales 1 ($ in Millions) $519 $552 $532.4 Comp Sales 2 (%) (3)% 3% (0.4)% Consolidated Adjusted EBITDA ($ in Millions) $12.5 $13.5 $13.0 New Franchised Clinic Openings (#) 30 35 29 1 System-wide sales include revenues at
Slide 16: On Track To Deliver Higher Profitability
On Track To Deliver Higher Profitability Post-Refranchising Initial / Short-Term Targets Enhanced Near-Term Profitability (est. mid-2026) Royalties & Fees Adj. EBITDA Margin Mid-2026 ~10% - 12% of System Sales 2024 2025 expected run rate Gross Margin 9% 12% ~19% - 21% ~83% - 85% of Revenue G&A Expen
Slide 17: Capital Allocation Priorities
Capital Allocation Priorities Investing In Growth Buy Back RD Share Initiatives Territories Repurchases NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 17
Slide 18: Sanjiv Razdan, CEO, President and Director
Sanjiv Razdan CEO, President and Director NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 18
Slide 19: Continued Progress on Reigniting Growth
Continued Progress on Reigniting Growth ✓ Y-o-Y Revenue and Adjusted EBITDA growth beginning to reflect transition to pure-play franchisor model ✓ Joint 2.0 transformation nearing completion and shifting focus to Joint 3.0 initiatives ✓ Capital allocation reflects conviction in long-term value of Th
Slide 20: Performance Metrics and Non-GAAP Measures
Performance Metrics and Non-GAAP Measures This presentation includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, man
Slide 21: Quarterly GAAP – Non-GAAP Reconciliation
Quarterly GAAP – Non-GAAP Reconciliation Three Months Ended March 31, 2026 2025 from from from Continuing Discontinued Net Continuing from Discontinued Net Operations Operations Operations Operations Operations Operations Non-GAAP Financial Data: Net income (loss) $ 1,102,791 $ 196,344 $ 1,299,135 $
Slide 22: Sanjiv Razdan, Scott Bowman, Richard Land contacts
Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com https://www.facebook.com/thejointchiro The Joint Corp. 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 @thejointchiro Scott Bowman, CFO scott.bowman@thejoint.com https://twitter.com/thejointchiro The Joint Corp. 16767